UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 648

Sortiert nach

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

Journal of rheumatology, 2009-06, Vol.36 (6), p.1273

2009

Volltextzugriff (PDF)

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Clinical journal of the American Society of Nephrology, 2013-11, Vol.8 (11), p.1960-1967

2013

Volltextzugriff (PDF)

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

Clinical cancer research, 2010-04, Vol.16 (7), p.2147-2156

2010

Volltextzugriff (PDF)

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

Clinical therapeutics, 2010-12, Vol.32 (14), p.2386-2397

2010

Volltextzugriff (PDF)

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors

Journal of rheumatology, 2011-07, Vol.38 (7), p.1385

2011

Volltextzugriff (PDF)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC geriatrics, 2012-03, Vol.12 (1), p.11-11, Article 11

2012

Volltextzugriff (PDF)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol

BMC musculoskeletal disorders, 2012-02, Vol.13 (1), p.15-15, Article 15

2012

Volltextzugriff (PDF)

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study

Arthritis & rheumatology (Hoboken, N.J.), 2017-12, Vol.69 (12), p.2386-2395

2017

Volltextzugriff (PDF)

Progress in measurement instruments for acute and chronic gout studies

Journal of rheumatology, 2009-10, Vol.36 (10), p.2346

2009

Volltextzugriff (PDF)

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity

Oncogene, 2019-06, Vol.38 (26), p.5294-5307

2019

Volltextzugriff (PDF)

Considering social values in the seafood sector using the Q-method

Marine policy, 2015-02, Vol.52, p.68-76

2015

Volltextzugriff (PDF)

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout

The New England journal of medicine, 2005-12, Vol.353 (23), p.2450-2461

2005

Volltextzugriff (PDF)

Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects

Nucleosides, nucleotides & nucleic acids, 2011-12, Vol.30 (12), p.1011-1017

2011

Volltextzugriff (PDF)

Renal function in gout: long-term treatment effects of febuxostat

Journal of clinical rheumatology, 2011-01, Vol.17 (1), p.7

2011

Volltextzugriff (PDF)

Tophaceous gout: quantitative evaluation by direct physical measurement

Journal of rheumatology, 2005-12, Vol.32 (12), p.2368

2005

Volltextzugriff (PDF)

Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

Postgraduate medicine, 2013-01, Vol.125 (1), p.106-114

2013

Volltextzugriff (PDF)

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Arthritis and rheumatism, 2008-11, Vol.59 (11), p.1540-1548

2008

Volltextzugriff (PDF)

Effects of Febuxostat in Early Gout

Arthritis & rheumatology (Hoboken, N.J.), 2017-12, Vol.69 (12), p.2386-2395

2017

Volltextzugriff (PDF)

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Journal of rheumatology, 2011-07, Vol.38 (7), p.1452

2011

Volltextzugriff (PDF)

Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol

Arthritis care & research (2010), 2012-02, Vol.64 (2), p.256-261

2012

Volltextzugriff (PDF)

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

Nucleosides, nucleotides & nucleic acids, 2008-06, Vol.27 (6-7), p.585-591

2008

Volltextzugriff (PDF)

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities

Journal of rheumatology, 2011-07, Vol.38 (7), p.1458

2011

Volltextzugriff (PDF)

Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials

Journal of rheumatology, 2011-07, Vol.38 (7), p.1467

2011

Volltextzugriff (PDF)

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Journal of rheumatology, 2011-07, Vol.38 (7), p.1462

2011

Volltextzugriff (PDF)

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and [beta]-catenin activity

Oncogene, 2019-06, Vol.38 (26), p.5294

2019

Volltextzugriff (PDF)

1 – 25 von 648

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(548)
Mit Volltextzugriff
(534)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones

Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials

Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

African American patients with gout: efficacy and safety of febuxostat vs allopurinol

Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study

Progress in measurement instruments for acute and chronic gout studies

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity

Considering social values in the seafood sector using the Q-method

Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout

Treating Hyperuricemia of Gout: Safety and Efficacy of Febuxostat and Allopurinol in Older Versus Younger Subjects

Renal function in gout: long-term treatment effects of febuxostat

Tophaceous gout: quantitative evaluation by direct physical measurement

Preservation of Renal Function during Gout Treatment with Febuxostat: A Quantitative Study

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

Effects of Febuxostat in Early Gout

Patient-reported outcomes in chronic gout: a report from OMERACT 10

Women with gout: Efficacy and safety of urate‐lowering with febuxostat and allopurinol

Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy

Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities

Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials

Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and [beta]-catenin activity

Suchergebnisse filtern